With the opening of the two child policy in China, the birth rate has increased by more than 15%. With the growth of the birth rate, postpartum hemorrhage has become one of the most common and dangerous clinical diseases in obstetrics and gynecology. The main reason is the lack of uterine contractions, followed by caesarean section, placenta previa and macrosomia.

With the postponement of the first birth age, the increase of caesarean section rate and the increase of macrosomia, the incidence of postpartum hemorrhage will increase. More attention will be paid to the treatment and prevention of postpartum hemorrhage, especially to the prevention of high-risk groups. At present, the clinical application of oxytocin for prevention or treatment.

Compared with the traditional oxytocin, the advantages of carbenicol oxytocin are more obvious. The clinical data both at home and abroad show that carbetoxine has a good advantage in the third stage of labor (the third stage of labor refers to a period of time from the delivery of the fetus to the delivery of the placenta).

This drug was rated as the most marketable drug in 2016 - the injection of oxytocin. Compared with oxytocin, the sales volume of the injection of oxytocin is close to that of oxytocin, but the retail price is still a hundred fold difference. Such a large gap is full of similarity space, which makes numerous agents compete for stoop, but the ideal is plump and the reality is bone feeling. Compared with the indications of oxytocin (for induced labor, oxytocin, postpartum and uterine bleeding caused by weakness or poor contractility after miscarriage; understanding of placental reserve function), the approved indications of carbetoxine are poor It's a huge distance. There's a saying that every woman who has a caesarean section may be a potential user of carbetoxine, which should only be regarded as a good wish. At present, there is a growing risk of using it beyond the scope of indications in clinical practice. At the same time, we also need to see that before the first enterprises to enter the market promote the products, the follow-up imitations have also been made They keep up.

From the clinical point of view, the carbetoxine, which is easier to operate and has better clinical effect, will gradually replace the common oxytocin as the first drug to prevent postpartum hemorrhage.

Carbetoxine will bind to the oxytocin receptor on the plasma membrane, increase the release of Ca2 + in cells through its coupled G protein, activate voltage sensitive calcium channels, increase the concentration of Ca2 + in the cytoplasm, and cause contraction of uterine smooth muscle, so as to prevent postpartum uterine atony.

Carbetoxine is a long-acting agonist of oxytocin receptor. Its action is similar to that of oxytocin released from the posterior pituitary.

Chengdu shengnuo biopharmaceutical Co., Ltd., as the first visit in China and with independent intellectual property rights, has been approved for listing.

At the same time, the company has GMP certification of carbetoxacin APIs, and has concentrated its efforts on bidding and market promotion to promote the development of carbetoxacin market and the achievement of the annual revenue target. At the same time, the listing of the drug enriches the company's core product categories, optimizes the company's product structure, and will have a significant positive impact on the company's performance. The most important thing is to improve product quality and quality value.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.